Akademik Veri Yönetim Sistemi
Turk Uroloji Dergisi, cilt.34, sa.1, ss.27-30, 2008 (SCI-Expanded)
Introduction: With aging, androgen levels decrease in men and a result of this hypogonadism symptoms occur. Therefore testosterone supplementation to treat hypogonadism is increasing. One of the possible complication for this treatment is increased prostate cancer risk. Although most authors agree that androgens are involved in the exacerbation of existing carcinoma for the prostate, the role of the androgens in this process is not clear. Attempts to demonstrate a correlation between hormone levels and prostate cancer have yielded inconsistent results. It is highly doubtful that when testosterone therapy is performed at older men, any potential prostate cancer promotion effect will be clinically manifested in the absence of already established cancer. As with any therapeutic regimen, careful monitoring of the patient receiving treatment is recommended and constitutes good medical care.